Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

This is a modest derisking event, not a value-creation inflection. For CYBN, completed enrollment mainly shifts the story from operational execution risk to pure binary readout risk; that tends to lower the discount rate only marginally until efficacy and tolerability are actually confirmed. The market should treat the next 2-3 quarters as financing-and-sentiment driven, with Q4 2026 the only catalyst that can materially change enterprise value.

The more interesting second-order effect is category validation. Strong commercial momentum in interventional psychiatry helps normalize physician behavior, clinic workflow, and payer education, which lowers future adoption friction for any differentiated adjunctive therapy. That is positive for CYBN if HLP003 works, but it also means JNJ’s platform can keep compounding before any new entrant reaches the market; in the near term, category growth likely accrues to the incumbent with the installed base and reimbursement leverage.

Contrarian view: the stock may be overreacting to enrollment completion because this does not improve the probability-adjusted NPV nearly as much as the market tends to imply. The real question is whether Phase 2 durability translates into a large-enough placebo-adjusted delta in Phase 3; if effect size compresses even modestly, the equity can re-rate sharply lower given the long timeline and likely need for capital. What would falsify the bullish setup is a safety signal, slower EMBRACE execution, or a weak topline readout versus the Phase 2 benchmark.